Clinical Trial Update: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the triple combination therapy DTRM-555 in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory non-Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Richter Transformation

Drugs mentioned

• DTRM-555

Snippet

Sponsor: Zhejiang DTRM Biopharma | Conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED